Skip to main content

Shopper 's Drug Mart at Queen and Carlaw in Toronto.

Tibor Kolley/The Globe & Mail

Here's a quick breakdown of the biggest deal in Canadian retail, the acquisition of Shoppers Drug Mart by Loblaw Cos.

Total price: $12.4-billion Breakdown: 54 per cent cash, 46 per cent stock.

Cash price: $61.54 a share.

Story continues below advertisement

Share consideration: 1.29417 Loblaw share.

Maximum cash outlay for Loblaw: $6.7-billion.

Maximum share issue for Loblaw: 119.9-million.

Ownership breakdown post-merger: Shoppers shareholders 29 per cent, George Weston Ltd. (Weston family holding company) 46 per cent.

Financing: $3.5-billion term loan and $1.6-billion bridge loan.

Pro forma 2012 revenue: $42-billion.

Pro forma 2012 earnings before interest, taxes, depreciation and amortization: $3-billion.

Story continues below advertisement

Pro forma 2012 free cash flow: $1-billion Accretion: "double digit" after accounting for amortization of intangibles.

Synergies: $300-million after three years. (Does not require store closings.) Store count: Loblaw has more than 1,000, Shoppers has 1,363.

(Boyd Erman is a Globe and Mail Capital Markets Reporter & Streetwise Columnist.)

Return to Streetwise home page.

The Globe has launched a Streetwise and ROB Insight newsletter, with content available exclusively to Globe Unlimited subscribers. Get the best of our exclusive insight and analysis delivered straight to your inbox in a daily e-mail curated by our editors. Sign up for it and other newsletters on our newsletters and alerts page.

Report an error Editorial code of conduct
Tickers mentioned in this story
Unchecking box will stop auto data updates
Due to technical reasons, we have temporarily removed commenting from our articles. We hope to have this fixed soon. Thank you for your patience. If you are looking to give feedback on our new site, please send it along to feedback@globeandmail.com. If you want to write a letter to the editor, please forward to letters@globeandmail.com.

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff. Non-subscribers can read and sort comments but will not be able to engage with them in any way. Click here to subscribe.

If you would like to write a letter to the editor, please forward it to letters@globeandmail.com. Readers can also interact with The Globe on Facebook and Twitter .

Welcome to The Globe and Mail’s comment community. This is a space where subscribers can engage with each other and Globe staff.

We aim to create a safe and valuable space for discussion and debate. That means:

  • Treat others as you wish to be treated
  • Criticize ideas, not people
  • Stay on topic
  • Avoid the use of toxic and offensive language
  • Flag bad behaviour

Comments that violate our community guidelines will be removed.

Read our community guidelines here

Discussion loading ...

Cannabis pro newsletter
To view this site properly, enable cookies in your browser. Read our privacy policy to learn more.
How to enable cookies